Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart patients to test app-based care for better blood pressure and cholesterol control

NCT ID NCT07332494

Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a smartphone app can help people with coronary heart disease better manage their blood pressure and cholesterol after having a stent placed. About 792 participants will either use the app for one year or receive usual care. The app reminds patients to check their blood pressure, tracks lab results, and suggests medication changes with doctor approval, aiming to improve heart health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
smartphone-based digital remote management platform
What this could lead to
If successful, this could provide an effective way for heart patients to manage their blood pressure and cholesterol at home, reducing the risk of future heart problems.
What could go wrong
This is an early-stage trial testing a new approach, so it may not prove better than standard care. Patients need to be comfortable using a smartphone app, which may not suit everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 792 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-75 years 2. Diagnosis of Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS) 3. Status post-successful percutaneous coronary intervention (PCI). 4. Possession of a smartphone and ability to operate the application (independently or with caregiver assistance). 5. Provision of written informed consent. Exclusion Criteria: 1. Heart Failure: NYHA Class III-IV or LVEF \< 40%. 2. Severe hepatic dysfunction (ALT/AST ≥3xULN or Total Bilirubin \>1.5 mg/dl) 3. Severe renal dysfunction (eGFR \< 30 ml/min/1.73m² or requiring dialysis) 4. Uncontrolled hypothyroidism (TSH \>1.5xULN or \>10 mIU/L, or unstable dosage within 6 weeks) 5. Life expectancy \< 1 year due to non-cardiovascular comorbidities 6. Severe sensory (hearing/vision) or cognitive impairment precluding device use 7. Conditions affecting adherence (e.g., substance use disorder, history of alcohol abuse)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary heart disease Percutaneous coronary intervention

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 13810720787

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University, Beijing, China

    Beijing, China

  • The First Affiliated Hospital of Dalian Medical University, Dalian, China

    Dalian, China

  • The First Hospital of Jilin University, Changchun, China

    Jilin City, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.